<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11069105</article-id>
    <article-id pub-id-type="pmid">38598476</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btae201</article-id>
    <article-id pub-id-type="publisher-id">btae201</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genetics and Population Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>shinyseg: a web application for flexible cosegregation and sensitivity analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3919-0011</contrib-id>
        <name>
          <surname>Carrizosa</surname>
          <given-names>Christian</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
        <xref rid="btae201-cor1" ref-type="corresp"/>
        <!--c.c.balmont@studmed.uio.no-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Undlien</surname>
          <given-names>Dag E</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="equal">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="equal">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9134-4962</contrib-id>
        <name>
          <surname>Vigeland</surname>
          <given-names>Magnus D</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Forensic Sciences, Oslo University Hospital</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Schwartz</surname>
          <given-names>Russell</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btae201-cor1">Corresponding author. Department of Medical Genetics, Oslo University Hospital and University of Oslo, 0424 Oslo, Norway. E-mail: <email>c.c.balmont@studmed.uio.no</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>5</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-10">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>40</volume>
    <issue>5</issue>
    <elocation-id>btae201</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="corrected-typeset">
        <day>03</day>
        <month>5</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btae201.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Cosegregation analysis is a powerful tool for identifying pathogenic genetic variants, but its implementation remains challenging. Existing software is either limited in scope or too demanding for many end users. Moreover, current solutions lack methods for assessing the robustness of cosegregation evidence, which is important due to its reliance on uncertain estimates.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We present shinyseg, a comprehensive web application for clinical cosegregation analysis. Our app streamlines penetrance specification based on either liability classes or epidemiological data such as risks, hazard ratios, and age of onset distribution. In addition, it incorporates sensitivity analyses to assess the robustness of cosegregation evidence, and offers support in clinical interpretation.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The shinyseg app is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, with documentation and complete R source code on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Research Council of Norway</institution>
            <institution-id institution-id-type="DOI">10.13039/501100005416</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>321043</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Cosegregation analysis is a powerful tool for identifying disease-associated genetic variants (<xref rid="btae201-B20" ref-type="bibr">Woodbury-Smith <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btae201-B3" ref-type="bibr">Caputo <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B5" ref-type="bibr">Cini <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). This method uses family data to assess if the segregation of a variant aligns with the inheritance of the disease in a pedigree, and it is particularly useful for identifying rare high-risk mutations. Free from the biases of population-based designs, cosegregation represents a separate evidence source in the American College of Medical Genetics and Genomics and Association of Molecular Pathology (ACMG-AMP) guidelines for clinical variant interpretation (<xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> 2015</xref>). However, its quantitative implementation (<xref rid="btae201-B11" ref-type="bibr">Petersen <italic toggle="yes">et al.</italic> 1998</xref>, <xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>, <xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) is technically challenging, which has resulted in the widespread use of less rigorous alternatives (<xref rid="btae201-B2" ref-type="bibr">Booth <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btae201-B10" ref-type="bibr">Perrino <italic toggle="yes">et al.</italic> 2020</xref>, <xref rid="btae201-B16" ref-type="bibr">Stankute <italic toggle="yes">et al.</italic> 2022</xref>).</p>
    <p>For many end users in clinical genetics, the main hurdle to cosegregation analysis is its reliance on specialised linkage software (<xref rid="btae201-B7" ref-type="bibr">Lathrop and Lalouel 1984</xref>, <xref rid="btae201-B15" ref-type="bibr">Schäffer <italic toggle="yes">et al.</italic> 1994</xref>). Following <xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> (2015)</xref> there have been various efforts to improve its accessibility, but these often entail a trade-off in flexibility. For instance, the meiosis-counting method of <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning (2016)</xref> works well in ideal examples with complete penetrance and no phenocopies, but is less useful otherwise. Similarly, the R package CoSeg (<xref rid="btae201-B12" ref-type="bibr">Ranola and Shirts 2016</xref>) is limited to a single autosomal dominant phenotype. Finally, the liability class approach of COOL (web server, <xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) and also segregatr (R package, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>) allows multiple phenotypes and more advanced penetrance models, but is impractical unless one employs COOL's built-in cancer estimates. A detailed software comparison is included in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S1</xref>.</p>
    <p>A significant limitation of current cosegregation software is the lack of sensitivity analyses. Each of the tools mentioned above outputs some likelihood-based statistic conditional on specified parameters (e.g. variant penetrances), yet reliable estimates for these are often unavailable. Ensuring the robustness of qualitative findings is vital since these can potentially impact a variant's clinical actionability. Regrettably, this is rarely done nor discussed in clinical applications, where cosegregation scores are typically taken at face value even when based on dubious penetrance parameters.</p>
    <p>To address these shortcomings, we introduce the web application shinyseg for clinical cosegregation analysis. This offers a parametric specification of the penetrance based on simple, explicit assumptions, and allows for sensitivity analysis to assess the robustness of the results. Additionally, it retains complete flexibility for advanced users. We demonstrate its utility with the practical example presented in this article.</p>
  </sec>
  <sec>
    <title>2 Implementation</title>
    <p>shinyseg is an R-based tool built with Shiny (<xref rid="btae201-B4" ref-type="bibr">Chang <italic toggle="yes">et al.</italic> 2024</xref>) and rhandsontable (<xref rid="btae201-B9" ref-type="bibr">Owen 2021</xref>). Pedigree data are handled by the pedsuite packages (<xref rid="btae201-B18" ref-type="bibr">Vigeland 2021</xref>), including segregatr performing the cosegregation calculations (<xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). The app features tips and notifications to ensure a smooth workflow, and all analyses may be stored, shared and retrieved by means of a tailor-made HTML report format.</p>
    <sec>
      <title>2.1 Data input</title>
      <p>Families can be added by uploading files in standard ped format, e.g. created with QuickPed (<xref rid="btae201-B19" ref-type="bibr">Vigeland 2022</xref>), or chosen from a dropdown list of basic cases. Additional information is entered in a table, including each member's phenotype, genotype, proband status, and age (of disease onset or censoring), all visualized in real-time on the pedigree plot.</p>
    </sec>
    <sec>
      <title>2.2 Model parameters</title>
      <p>The default variant frequency is 0.001, but it can be adjusted as needed. The inheritance pattern is made of two choices regarding chromosome (autosomal, X-linked) and dominance (dominant, recessive, incomplete). Penetrance specification may be done in two ways.</p>
      <list list-type="bullet">
        <list-item>
          <p><italic toggle="yes">Relative risk.</italic> We introduce a parametric version of COOL's (<xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) approach based on: (i) the baseline (phenocopy) lifetime risk and age of onset, and (ii) the hazard ratios over age. The user may enter these parameters directly, or provide incidence data from which optimal parameters are inferred by the program. Variant penetrances are automatically computed following a survival model (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S2</xref> for details).</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Liability classes.</italic> Penetrance values for each class may be written interactively or uploaded from a suitable file.</p>
        </list-item>
      </list>
    </sec>
    <sec>
      <title>2.3 Cosegregation evidence</title>
      <p>With all necessary information in place, shinyseg computes the full-likelihood Bayes factor (FLB) for the variant's pathogenicity (<xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>). We chose this metric over the cosegregation likelihood ratio (<xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) because of its greater flexibility, not being limited to a single introduction of the variant. A key for translating the cosegregation evidence into the ACMG-AMP framework is provided, using <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning's (2016)</xref> thresholds. Furthermore, robustness of the results can be assessed with contour plots of the FLB when varying the analysis parameters.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>We showcase shinyseg by analyzing the pedigree in <xref rid="btae201-F1" ref-type="fig">Fig. 1A</xref>. This family is based on a real case where four members affected by a rare connective tissue disorder (onset: 30–60 years) were found to share a rare autosomal variant. Among the five unaffected individuals tested, two from the youngest generation were also carriers. Moreover, the proband's grandfather is likely an obligate carrier, but he remained asymptomatic until his death in his 40s. Penetrance estimates are not available. Henceforth, we will assume complete dominance and a population variant frequency of 0.001.</p>
    <fig position="float" id="btae201-F1">
      <label>Figure 1.</label>
      <caption>
        <p>(A) Medical pedigree showing phenotype (empty: unaffected; filled: affected; question mark: unknown), age (onset or censoring) and carriership status (+: carrier; –: non-carrier). Crossed individuals are deceased; the arrow indicates the proband. (B) Sensitivity analysis displaying contours of the FLB as a function of the risk in carriers and non-carriers under two penetrance models. The crosses indicate the main results, while the dotted lines enclose a region of reasonable parameter values.</p>
      </caption>
      <graphic xlink:href="btae201f1" position="float"/>
    </fig>
    <p>A naïve segregation analysis in this family could entail setting a single risk parameter for non-carriers (phenocopy rate) and another for carriers (penetrance). Conservative values of 0.001 and 0.90, respectively, yield an FLB of 3.2, which is inconclusive evidence for the variant's pathogenicity (FLB &lt; 8, <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning 2016</xref>). However, this conclusion is highly sensitive to the parameter values (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, left). In particular, reducing the carriers' risk amplifies the evidence, a consequence of the unaffected carriers.</p>
    <p>In order to better capture the apparent late-onset nature of the disease in this family, a possible approach is to introduce age-specific liability classes. Yet, with limited disease knowledge, this would require speculative estimates of the penetrance values. Furthermore, as each liability class adds multiple new parameters, sensitivity analyses become increasingly unwieldy.</p>
    <p>Instead, we use the <italic toggle="yes">relative risk</italic> mode of shinyseg, as it streamlines this process while ensuring transparent assumptions. For instance, using the same risk values as before and an age of onset for phenocopies of 60 ± 15 years, we obtain an FLB score of 30.3 under a proportional hazards model, i.e. constant relative risk. This indicates that our data actually provides moderate evidence for pathogenicity (FLB &gt; 16), a conclusion which is highly robust to the lifetime risk parameters (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, right).</p>
  </sec>
  <sec>
    <title>4 Conclusion</title>
    <p>We present shinyseg, an app for clinical cosegregation analysis that emphasizes flexible penetrance specification and sensitivity analysis. Suited to varying levels of expertise, our app encourages transparent modelling assumptions and guides the user toward well-informed decisions.</p>
    <p>shinyseg is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, and runs in all common browsers. Documentation and complete source code can be found on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btae201_Supplementary_Data</label>
      <media xlink:href="btae201_supplementary_data.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work has been supported by the Research Council of Norway [321043 to D.E.U.].</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>All code and data are accessible at <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btae201-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Belman</surname><given-names>S</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>MT</given-names></string-name>, <string-name><surname>Spurdle</surname><given-names>AB</given-names></string-name></person-group><etal>et al</etal><article-title>Considerations in assessing germline variant pathogenicity using cosegregation analysis</article-title>. <source>Genet Med</source><year>2020</year>;<volume>22</volume>:<fpage>2052</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32773770</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Booth</surname><given-names>KT</given-names></string-name>, <string-name><surname>Askew</surname><given-names>JW</given-names></string-name>, <string-name><surname>Talebizadeh</surname><given-names>Z</given-names></string-name></person-group><etal>et al</etal><article-title>Splice-altering variant in COL11A1 as a cause of nonsyndromic hearing loss DFNA37</article-title>. <source>Genet Med</source><year>2019</year>;<volume>21</volume>:<fpage>948</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">30245514</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caputo</surname><given-names>SM</given-names></string-name>, <string-name><surname>Golmard</surname><given-names>L</given-names></string-name>, <string-name><surname>Leone</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach</article-title>. <source>Am J Hum Genet</source><year>2021</year>;<volume>108</volume>:<fpage>1907</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">34597585</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B4">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name><surname>Allaire</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal> shiny: web application framework for R. <year>2024</year>. R package version 1.8.1.1, <ext-link xlink:href="https://cran.r-project.org/package=shiny" ext-link-type="uri">https://cran.r-project.org/package=shiny</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cini</surname><given-names>G</given-names></string-name>, <string-name><surname>Carnevali</surname><given-names>I</given-names></string-name>, <string-name><surname>Sahnane</surname><given-names>N</given-names></string-name></person-group><etal>et al</etal><article-title>Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene</article-title>. <source>Cancer Genet</source><year>2021</year>;<volume>254-255</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33516942</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarvik</surname><given-names>GP</given-names></string-name>, <string-name><surname>Browning</surname><given-names>BL.</given-names></string-name></person-group><article-title>Consideration of cosegregation in the pathogenicity classification of genomic variants</article-title>. <source>Am J Hum Genet</source><year>2016</year>;<volume>98</volume>:<fpage>1077</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">27236918</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lathrop</surname><given-names>GM</given-names></string-name>, <string-name><surname>Lalouel</surname><given-names>JM.</given-names></string-name></person-group><article-title>Easy calculations of lod scores and genetic risks on small computers</article-title>. <source>Am J Hum Genet</source><year>1984</year>;<volume>36</volume>:<fpage>460</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">6585139</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohammadi</surname><given-names>L</given-names></string-name>, <string-name><surname>Vreeswijk</surname><given-names>MP</given-names></string-name>, <string-name><surname>Oldenburg</surname><given-names>R</given-names></string-name></person-group><etal>et al</etal><article-title>A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example</article-title>. <source>BMC Cancer</source><year>2009</year>;<volume>9</volume>:<fpage>211</fpage>.<pub-id pub-id-type="pmid">19563646</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B9">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Owen</surname><given-names>J.</given-names></string-name></person-group> rhandsontable: interface to the ‘Handsontable.js’ library. <year>2021</year>. R package version 0.3.8, <ext-link xlink:href="https://cran.r-project.org/package=rhandsontable" ext-link-type="uri">https://cran.r-project.org/package=rhandsontable</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perrino</surname><given-names>PA</given-names></string-name>, <string-name><surname>Talbot</surname><given-names>L</given-names></string-name>, <string-name><surname>Kirkland</surname><given-names>R</given-names></string-name></person-group>; <collab>WGS500 Consortium</collab><etal>et al</etal><article-title>Multi-level evidence of an allelic hierarchy of USH2A variants in hearing, auditory processing and speech/language outcomes</article-title>. <source>Commun Biol</source><year>2020</year>;<volume>3</volume>:<fpage>180</fpage>.<pub-id pub-id-type="pmid">32313182</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petersen</surname><given-names>GM</given-names></string-name>, <string-name><surname>Parmigiani</surname><given-names>G</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>D.</given-names></string-name></person-group><article-title>Missense mutations in disease genes: a bayesian approach to evaluate causality</article-title>. <source>Am J Hum Genet</source><year>1998</year>;<volume>62</volume>:<fpage>1516</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">9585599</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B12">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ranola</surname><given-names>J</given-names></string-name>, <string-name><surname>Shirts</surname><given-names>B.</given-names></string-name></person-group> CoSeg R Package. <year>2016</year>. R package version 0.55, <ext-link xlink:href="https://r-forge.r-project.org/projects/coseg/" ext-link-type="uri">https://r-forge.r-project.org/projects/coseg/</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratajska</surname><given-names>A</given-names></string-name>, <string-name><surname>Vigeland</surname><given-names>MD</given-names></string-name>, <string-name><surname>Wirgenes</surname><given-names>KV</given-names></string-name></person-group><etal>et al</etal><article-title>The use of segregation analysis in interpretation of sequence variants in SMAD3: a case report</article-title>. <source>Mol Genet Genomic Med</source><year>2023</year>;<volume>11</volume>:<fpage>e2107</fpage>.<pub-id pub-id-type="pmid">36495030</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>S</given-names></string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name></person-group>; <collab>ACMG Laboratory Quality Assurance Committee</collab><etal>et al</etal><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schäffer</surname><given-names>AA</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>SK</given-names></string-name>, <string-name><surname>Shriram</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Avoiding recomputation in linkage analysis</article-title>. <source>Hum Hered</source><year>1994</year>;<volume>44</volume>:<fpage>225</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">8056435</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stankute</surname><given-names>I</given-names></string-name>, <string-name><surname>Kazlauskiene</surname><given-names>M</given-names></string-name>, <string-name><surname>Blouin</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Co-segregation analysis and functional trial in vivo of candidate genes for monogenic diabetes</article-title>. <source>BMJ Open Diabetes Res Care</source><year>2022</year>;<volume>10</volume>:<fpage>e003038</fpage>.</mixed-citation>
    </ref>
    <ref id="btae201-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname><given-names>D</given-names></string-name>, <string-name><surname>Easton</surname><given-names>DF</given-names></string-name>, <string-name><surname>Goldgar</surname><given-names>DE.</given-names></string-name></person-group><article-title>A full-likelihood method for the evaluation of causality of sequence variants from family data</article-title>. <source>Am J Hum Genet</source><year>2003</year>;<volume>73</volume>:<fpage>652</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">12900794</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B18">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><source>Pedigree Analysis in R</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>2021</year>.</mixed-citation>
    </ref>
    <ref id="btae201-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><article-title>QuickPed: an online tool for drawing pedigrees and analysing relatedness</article-title>. <source>BMC Bioinformatics </source><year>2022</year>;<volume>23</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">35672681</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodbury-Smith</surname><given-names>M</given-names></string-name>, <string-name><surname>Deneault</surname><given-names>E</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>RKC</given-names></string-name></person-group><etal>et al</etal><article-title>Mutations in RAB39B in individuals with intellectual disability, autism spectrum disorder, and macrocephaly</article-title>. <source>Mol Autism</source><year>2017</year>;<volume>8</volume>:<fpage>59</fpage>.<pub-id pub-id-type="pmid">29152164</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11069105</article-id>
    <article-id pub-id-type="pmid">38598476</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btae201</article-id>
    <article-id pub-id-type="publisher-id">btae201</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genetics and Population Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>shinyseg: a web application for flexible cosegregation and sensitivity analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3919-0011</contrib-id>
        <name>
          <surname>Carrizosa</surname>
          <given-names>Christian</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
        <xref rid="btae201-cor1" ref-type="corresp"/>
        <!--c.c.balmont@studmed.uio.no-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Undlien</surname>
          <given-names>Dag E</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="equal">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="equal">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9134-4962</contrib-id>
        <name>
          <surname>Vigeland</surname>
          <given-names>Magnus D</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Forensic Sciences, Oslo University Hospital</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Schwartz</surname>
          <given-names>Russell</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btae201-cor1">Corresponding author. Department of Medical Genetics, Oslo University Hospital and University of Oslo, 0424 Oslo, Norway. E-mail: <email>c.c.balmont@studmed.uio.no</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>5</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-10">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>40</volume>
    <issue>5</issue>
    <elocation-id>btae201</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="corrected-typeset">
        <day>03</day>
        <month>5</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btae201.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Cosegregation analysis is a powerful tool for identifying pathogenic genetic variants, but its implementation remains challenging. Existing software is either limited in scope or too demanding for many end users. Moreover, current solutions lack methods for assessing the robustness of cosegregation evidence, which is important due to its reliance on uncertain estimates.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We present shinyseg, a comprehensive web application for clinical cosegregation analysis. Our app streamlines penetrance specification based on either liability classes or epidemiological data such as risks, hazard ratios, and age of onset distribution. In addition, it incorporates sensitivity analyses to assess the robustness of cosegregation evidence, and offers support in clinical interpretation.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The shinyseg app is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, with documentation and complete R source code on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Research Council of Norway</institution>
            <institution-id institution-id-type="DOI">10.13039/501100005416</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>321043</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Cosegregation analysis is a powerful tool for identifying disease-associated genetic variants (<xref rid="btae201-B20" ref-type="bibr">Woodbury-Smith <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btae201-B3" ref-type="bibr">Caputo <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B5" ref-type="bibr">Cini <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). This method uses family data to assess if the segregation of a variant aligns with the inheritance of the disease in a pedigree, and it is particularly useful for identifying rare high-risk mutations. Free from the biases of population-based designs, cosegregation represents a separate evidence source in the American College of Medical Genetics and Genomics and Association of Molecular Pathology (ACMG-AMP) guidelines for clinical variant interpretation (<xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> 2015</xref>). However, its quantitative implementation (<xref rid="btae201-B11" ref-type="bibr">Petersen <italic toggle="yes">et al.</italic> 1998</xref>, <xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>, <xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) is technically challenging, which has resulted in the widespread use of less rigorous alternatives (<xref rid="btae201-B2" ref-type="bibr">Booth <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btae201-B10" ref-type="bibr">Perrino <italic toggle="yes">et al.</italic> 2020</xref>, <xref rid="btae201-B16" ref-type="bibr">Stankute <italic toggle="yes">et al.</italic> 2022</xref>).</p>
    <p>For many end users in clinical genetics, the main hurdle to cosegregation analysis is its reliance on specialised linkage software (<xref rid="btae201-B7" ref-type="bibr">Lathrop and Lalouel 1984</xref>, <xref rid="btae201-B15" ref-type="bibr">Schäffer <italic toggle="yes">et al.</italic> 1994</xref>). Following <xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> (2015)</xref> there have been various efforts to improve its accessibility, but these often entail a trade-off in flexibility. For instance, the meiosis-counting method of <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning (2016)</xref> works well in ideal examples with complete penetrance and no phenocopies, but is less useful otherwise. Similarly, the R package CoSeg (<xref rid="btae201-B12" ref-type="bibr">Ranola and Shirts 2016</xref>) is limited to a single autosomal dominant phenotype. Finally, the liability class approach of COOL (web server, <xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) and also segregatr (R package, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>) allows multiple phenotypes and more advanced penetrance models, but is impractical unless one employs COOL's built-in cancer estimates. A detailed software comparison is included in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S1</xref>.</p>
    <p>A significant limitation of current cosegregation software is the lack of sensitivity analyses. Each of the tools mentioned above outputs some likelihood-based statistic conditional on specified parameters (e.g. variant penetrances), yet reliable estimates for these are often unavailable. Ensuring the robustness of qualitative findings is vital since these can potentially impact a variant's clinical actionability. Regrettably, this is rarely done nor discussed in clinical applications, where cosegregation scores are typically taken at face value even when based on dubious penetrance parameters.</p>
    <p>To address these shortcomings, we introduce the web application shinyseg for clinical cosegregation analysis. This offers a parametric specification of the penetrance based on simple, explicit assumptions, and allows for sensitivity analysis to assess the robustness of the results. Additionally, it retains complete flexibility for advanced users. We demonstrate its utility with the practical example presented in this article.</p>
  </sec>
  <sec>
    <title>2 Implementation</title>
    <p>shinyseg is an R-based tool built with Shiny (<xref rid="btae201-B4" ref-type="bibr">Chang <italic toggle="yes">et al.</italic> 2024</xref>) and rhandsontable (<xref rid="btae201-B9" ref-type="bibr">Owen 2021</xref>). Pedigree data are handled by the pedsuite packages (<xref rid="btae201-B18" ref-type="bibr">Vigeland 2021</xref>), including segregatr performing the cosegregation calculations (<xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). The app features tips and notifications to ensure a smooth workflow, and all analyses may be stored, shared and retrieved by means of a tailor-made HTML report format.</p>
    <sec>
      <title>2.1 Data input</title>
      <p>Families can be added by uploading files in standard ped format, e.g. created with QuickPed (<xref rid="btae201-B19" ref-type="bibr">Vigeland 2022</xref>), or chosen from a dropdown list of basic cases. Additional information is entered in a table, including each member's phenotype, genotype, proband status, and age (of disease onset or censoring), all visualized in real-time on the pedigree plot.</p>
    </sec>
    <sec>
      <title>2.2 Model parameters</title>
      <p>The default variant frequency is 0.001, but it can be adjusted as needed. The inheritance pattern is made of two choices regarding chromosome (autosomal, X-linked) and dominance (dominant, recessive, incomplete). Penetrance specification may be done in two ways.</p>
      <list list-type="bullet">
        <list-item>
          <p><italic toggle="yes">Relative risk.</italic> We introduce a parametric version of COOL's (<xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) approach based on: (i) the baseline (phenocopy) lifetime risk and age of onset, and (ii) the hazard ratios over age. The user may enter these parameters directly, or provide incidence data from which optimal parameters are inferred by the program. Variant penetrances are automatically computed following a survival model (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S2</xref> for details).</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Liability classes.</italic> Penetrance values for each class may be written interactively or uploaded from a suitable file.</p>
        </list-item>
      </list>
    </sec>
    <sec>
      <title>2.3 Cosegregation evidence</title>
      <p>With all necessary information in place, shinyseg computes the full-likelihood Bayes factor (FLB) for the variant's pathogenicity (<xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>). We chose this metric over the cosegregation likelihood ratio (<xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) because of its greater flexibility, not being limited to a single introduction of the variant. A key for translating the cosegregation evidence into the ACMG-AMP framework is provided, using <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning's (2016)</xref> thresholds. Furthermore, robustness of the results can be assessed with contour plots of the FLB when varying the analysis parameters.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>We showcase shinyseg by analyzing the pedigree in <xref rid="btae201-F1" ref-type="fig">Fig. 1A</xref>. This family is based on a real case where four members affected by a rare connective tissue disorder (onset: 30–60 years) were found to share a rare autosomal variant. Among the five unaffected individuals tested, two from the youngest generation were also carriers. Moreover, the proband's grandfather is likely an obligate carrier, but he remained asymptomatic until his death in his 40s. Penetrance estimates are not available. Henceforth, we will assume complete dominance and a population variant frequency of 0.001.</p>
    <fig position="float" id="btae201-F1">
      <label>Figure 1.</label>
      <caption>
        <p>(A) Medical pedigree showing phenotype (empty: unaffected; filled: affected; question mark: unknown), age (onset or censoring) and carriership status (+: carrier; –: non-carrier). Crossed individuals are deceased; the arrow indicates the proband. (B) Sensitivity analysis displaying contours of the FLB as a function of the risk in carriers and non-carriers under two penetrance models. The crosses indicate the main results, while the dotted lines enclose a region of reasonable parameter values.</p>
      </caption>
      <graphic xlink:href="btae201f1" position="float"/>
    </fig>
    <p>A naïve segregation analysis in this family could entail setting a single risk parameter for non-carriers (phenocopy rate) and another for carriers (penetrance). Conservative values of 0.001 and 0.90, respectively, yield an FLB of 3.2, which is inconclusive evidence for the variant's pathogenicity (FLB &lt; 8, <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning 2016</xref>). However, this conclusion is highly sensitive to the parameter values (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, left). In particular, reducing the carriers' risk amplifies the evidence, a consequence of the unaffected carriers.</p>
    <p>In order to better capture the apparent late-onset nature of the disease in this family, a possible approach is to introduce age-specific liability classes. Yet, with limited disease knowledge, this would require speculative estimates of the penetrance values. Furthermore, as each liability class adds multiple new parameters, sensitivity analyses become increasingly unwieldy.</p>
    <p>Instead, we use the <italic toggle="yes">relative risk</italic> mode of shinyseg, as it streamlines this process while ensuring transparent assumptions. For instance, using the same risk values as before and an age of onset for phenocopies of 60 ± 15 years, we obtain an FLB score of 30.3 under a proportional hazards model, i.e. constant relative risk. This indicates that our data actually provides moderate evidence for pathogenicity (FLB &gt; 16), a conclusion which is highly robust to the lifetime risk parameters (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, right).</p>
  </sec>
  <sec>
    <title>4 Conclusion</title>
    <p>We present shinyseg, an app for clinical cosegregation analysis that emphasizes flexible penetrance specification and sensitivity analysis. Suited to varying levels of expertise, our app encourages transparent modelling assumptions and guides the user toward well-informed decisions.</p>
    <p>shinyseg is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, and runs in all common browsers. Documentation and complete source code can be found on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btae201_Supplementary_Data</label>
      <media xlink:href="btae201_supplementary_data.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work has been supported by the Research Council of Norway [321043 to D.E.U.].</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>All code and data are accessible at <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btae201-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Belman</surname><given-names>S</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>MT</given-names></string-name>, <string-name><surname>Spurdle</surname><given-names>AB</given-names></string-name></person-group><etal>et al</etal><article-title>Considerations in assessing germline variant pathogenicity using cosegregation analysis</article-title>. <source>Genet Med</source><year>2020</year>;<volume>22</volume>:<fpage>2052</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32773770</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Booth</surname><given-names>KT</given-names></string-name>, <string-name><surname>Askew</surname><given-names>JW</given-names></string-name>, <string-name><surname>Talebizadeh</surname><given-names>Z</given-names></string-name></person-group><etal>et al</etal><article-title>Splice-altering variant in COL11A1 as a cause of nonsyndromic hearing loss DFNA37</article-title>. <source>Genet Med</source><year>2019</year>;<volume>21</volume>:<fpage>948</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">30245514</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caputo</surname><given-names>SM</given-names></string-name>, <string-name><surname>Golmard</surname><given-names>L</given-names></string-name>, <string-name><surname>Leone</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach</article-title>. <source>Am J Hum Genet</source><year>2021</year>;<volume>108</volume>:<fpage>1907</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">34597585</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B4">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name><surname>Allaire</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal> shiny: web application framework for R. <year>2024</year>. R package version 1.8.1.1, <ext-link xlink:href="https://cran.r-project.org/package=shiny" ext-link-type="uri">https://cran.r-project.org/package=shiny</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cini</surname><given-names>G</given-names></string-name>, <string-name><surname>Carnevali</surname><given-names>I</given-names></string-name>, <string-name><surname>Sahnane</surname><given-names>N</given-names></string-name></person-group><etal>et al</etal><article-title>Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene</article-title>. <source>Cancer Genet</source><year>2021</year>;<volume>254-255</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33516942</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarvik</surname><given-names>GP</given-names></string-name>, <string-name><surname>Browning</surname><given-names>BL.</given-names></string-name></person-group><article-title>Consideration of cosegregation in the pathogenicity classification of genomic variants</article-title>. <source>Am J Hum Genet</source><year>2016</year>;<volume>98</volume>:<fpage>1077</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">27236918</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lathrop</surname><given-names>GM</given-names></string-name>, <string-name><surname>Lalouel</surname><given-names>JM.</given-names></string-name></person-group><article-title>Easy calculations of lod scores and genetic risks on small computers</article-title>. <source>Am J Hum Genet</source><year>1984</year>;<volume>36</volume>:<fpage>460</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">6585139</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohammadi</surname><given-names>L</given-names></string-name>, <string-name><surname>Vreeswijk</surname><given-names>MP</given-names></string-name>, <string-name><surname>Oldenburg</surname><given-names>R</given-names></string-name></person-group><etal>et al</etal><article-title>A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example</article-title>. <source>BMC Cancer</source><year>2009</year>;<volume>9</volume>:<fpage>211</fpage>.<pub-id pub-id-type="pmid">19563646</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B9">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Owen</surname><given-names>J.</given-names></string-name></person-group> rhandsontable: interface to the ‘Handsontable.js’ library. <year>2021</year>. R package version 0.3.8, <ext-link xlink:href="https://cran.r-project.org/package=rhandsontable" ext-link-type="uri">https://cran.r-project.org/package=rhandsontable</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perrino</surname><given-names>PA</given-names></string-name>, <string-name><surname>Talbot</surname><given-names>L</given-names></string-name>, <string-name><surname>Kirkland</surname><given-names>R</given-names></string-name></person-group>; <collab>WGS500 Consortium</collab><etal>et al</etal><article-title>Multi-level evidence of an allelic hierarchy of USH2A variants in hearing, auditory processing and speech/language outcomes</article-title>. <source>Commun Biol</source><year>2020</year>;<volume>3</volume>:<fpage>180</fpage>.<pub-id pub-id-type="pmid">32313182</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petersen</surname><given-names>GM</given-names></string-name>, <string-name><surname>Parmigiani</surname><given-names>G</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>D.</given-names></string-name></person-group><article-title>Missense mutations in disease genes: a bayesian approach to evaluate causality</article-title>. <source>Am J Hum Genet</source><year>1998</year>;<volume>62</volume>:<fpage>1516</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">9585599</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B12">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ranola</surname><given-names>J</given-names></string-name>, <string-name><surname>Shirts</surname><given-names>B.</given-names></string-name></person-group> CoSeg R Package. <year>2016</year>. R package version 0.55, <ext-link xlink:href="https://r-forge.r-project.org/projects/coseg/" ext-link-type="uri">https://r-forge.r-project.org/projects/coseg/</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratajska</surname><given-names>A</given-names></string-name>, <string-name><surname>Vigeland</surname><given-names>MD</given-names></string-name>, <string-name><surname>Wirgenes</surname><given-names>KV</given-names></string-name></person-group><etal>et al</etal><article-title>The use of segregation analysis in interpretation of sequence variants in SMAD3: a case report</article-title>. <source>Mol Genet Genomic Med</source><year>2023</year>;<volume>11</volume>:<fpage>e2107</fpage>.<pub-id pub-id-type="pmid">36495030</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>S</given-names></string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name></person-group>; <collab>ACMG Laboratory Quality Assurance Committee</collab><etal>et al</etal><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schäffer</surname><given-names>AA</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>SK</given-names></string-name>, <string-name><surname>Shriram</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Avoiding recomputation in linkage analysis</article-title>. <source>Hum Hered</source><year>1994</year>;<volume>44</volume>:<fpage>225</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">8056435</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stankute</surname><given-names>I</given-names></string-name>, <string-name><surname>Kazlauskiene</surname><given-names>M</given-names></string-name>, <string-name><surname>Blouin</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Co-segregation analysis and functional trial in vivo of candidate genes for monogenic diabetes</article-title>. <source>BMJ Open Diabetes Res Care</source><year>2022</year>;<volume>10</volume>:<fpage>e003038</fpage>.</mixed-citation>
    </ref>
    <ref id="btae201-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname><given-names>D</given-names></string-name>, <string-name><surname>Easton</surname><given-names>DF</given-names></string-name>, <string-name><surname>Goldgar</surname><given-names>DE.</given-names></string-name></person-group><article-title>A full-likelihood method for the evaluation of causality of sequence variants from family data</article-title>. <source>Am J Hum Genet</source><year>2003</year>;<volume>73</volume>:<fpage>652</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">12900794</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B18">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><source>Pedigree Analysis in R</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>2021</year>.</mixed-citation>
    </ref>
    <ref id="btae201-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><article-title>QuickPed: an online tool for drawing pedigrees and analysing relatedness</article-title>. <source>BMC Bioinformatics </source><year>2022</year>;<volume>23</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">35672681</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodbury-Smith</surname><given-names>M</given-names></string-name>, <string-name><surname>Deneault</surname><given-names>E</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>RKC</given-names></string-name></person-group><etal>et al</etal><article-title>Mutations in RAB39B in individuals with intellectual disability, autism spectrum disorder, and macrocephaly</article-title>. <source>Mol Autism</source><year>2017</year>;<volume>8</volume>:<fpage>59</fpage>.<pub-id pub-id-type="pmid">29152164</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11069105</article-id>
    <article-id pub-id-type="pmid">38598476</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btae201</article-id>
    <article-id pub-id-type="publisher-id">btae201</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genetics and Population Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>shinyseg: a web application for flexible cosegregation and sensitivity analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3919-0011</contrib-id>
        <name>
          <surname>Carrizosa</surname>
          <given-names>Christian</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
        <xref rid="btae201-cor1" ref-type="corresp"/>
        <!--c.c.balmont@studmed.uio.no-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Undlien</surname>
          <given-names>Dag E</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="equal">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="equal">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Medical Genetics, Oslo University Hospital and University of Oslo</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9134-4962</contrib-id>
        <name>
          <surname>Vigeland</surname>
          <given-names>Magnus D</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>Department of Forensic Sciences, Oslo University Hospital</institution>, 0424 Oslo, <country country="NO">Norway</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Schwartz</surname>
          <given-names>Russell</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btae201-cor1">Corresponding author. Department of Medical Genetics, Oslo University Hospital and University of Oslo, 0424 Oslo, Norway. E-mail: <email>c.c.balmont@studmed.uio.no</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>5</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-10">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>40</volume>
    <issue>5</issue>
    <elocation-id>btae201</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="corrected-typeset">
        <day>03</day>
        <month>5</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btae201.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Cosegregation analysis is a powerful tool for identifying pathogenic genetic variants, but its implementation remains challenging. Existing software is either limited in scope or too demanding for many end users. Moreover, current solutions lack methods for assessing the robustness of cosegregation evidence, which is important due to its reliance on uncertain estimates.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We present shinyseg, a comprehensive web application for clinical cosegregation analysis. Our app streamlines penetrance specification based on either liability classes or epidemiological data such as risks, hazard ratios, and age of onset distribution. In addition, it incorporates sensitivity analyses to assess the robustness of cosegregation evidence, and offers support in clinical interpretation.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The shinyseg app is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, with documentation and complete R source code on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Research Council of Norway</institution>
            <institution-id institution-id-type="DOI">10.13039/501100005416</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>321043</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Cosegregation analysis is a powerful tool for identifying disease-associated genetic variants (<xref rid="btae201-B20" ref-type="bibr">Woodbury-Smith <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btae201-B3" ref-type="bibr">Caputo <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B5" ref-type="bibr">Cini <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). This method uses family data to assess if the segregation of a variant aligns with the inheritance of the disease in a pedigree, and it is particularly useful for identifying rare high-risk mutations. Free from the biases of population-based designs, cosegregation represents a separate evidence source in the American College of Medical Genetics and Genomics and Association of Molecular Pathology (ACMG-AMP) guidelines for clinical variant interpretation (<xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> 2015</xref>). However, its quantitative implementation (<xref rid="btae201-B11" ref-type="bibr">Petersen <italic toggle="yes">et al.</italic> 1998</xref>, <xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>, <xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) is technically challenging, which has resulted in the widespread use of less rigorous alternatives (<xref rid="btae201-B2" ref-type="bibr">Booth <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btae201-B10" ref-type="bibr">Perrino <italic toggle="yes">et al.</italic> 2020</xref>, <xref rid="btae201-B16" ref-type="bibr">Stankute <italic toggle="yes">et al.</italic> 2022</xref>).</p>
    <p>For many end users in clinical genetics, the main hurdle to cosegregation analysis is its reliance on specialised linkage software (<xref rid="btae201-B7" ref-type="bibr">Lathrop and Lalouel 1984</xref>, <xref rid="btae201-B15" ref-type="bibr">Schäffer <italic toggle="yes">et al.</italic> 1994</xref>). Following <xref rid="btae201-B14" ref-type="bibr">Richards <italic toggle="yes">et al.</italic> (2015)</xref> there have been various efforts to improve its accessibility, but these often entail a trade-off in flexibility. For instance, the meiosis-counting method of <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning (2016)</xref> works well in ideal examples with complete penetrance and no phenocopies, but is less useful otherwise. Similarly, the R package CoSeg (<xref rid="btae201-B12" ref-type="bibr">Ranola and Shirts 2016</xref>) is limited to a single autosomal dominant phenotype. Finally, the liability class approach of COOL (web server, <xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) and also segregatr (R package, <xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>) allows multiple phenotypes and more advanced penetrance models, but is impractical unless one employs COOL's built-in cancer estimates. A detailed software comparison is included in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S1</xref>.</p>
    <p>A significant limitation of current cosegregation software is the lack of sensitivity analyses. Each of the tools mentioned above outputs some likelihood-based statistic conditional on specified parameters (e.g. variant penetrances), yet reliable estimates for these are often unavailable. Ensuring the robustness of qualitative findings is vital since these can potentially impact a variant's clinical actionability. Regrettably, this is rarely done nor discussed in clinical applications, where cosegregation scores are typically taken at face value even when based on dubious penetrance parameters.</p>
    <p>To address these shortcomings, we introduce the web application shinyseg for clinical cosegregation analysis. This offers a parametric specification of the penetrance based on simple, explicit assumptions, and allows for sensitivity analysis to assess the robustness of the results. Additionally, it retains complete flexibility for advanced users. We demonstrate its utility with the practical example presented in this article.</p>
  </sec>
  <sec>
    <title>2 Implementation</title>
    <p>shinyseg is an R-based tool built with Shiny (<xref rid="btae201-B4" ref-type="bibr">Chang <italic toggle="yes">et al.</italic> 2024</xref>) and rhandsontable (<xref rid="btae201-B9" ref-type="bibr">Owen 2021</xref>). Pedigree data are handled by the pedsuite packages (<xref rid="btae201-B18" ref-type="bibr">Vigeland 2021</xref>), including segregatr performing the cosegregation calculations (<xref rid="btae201-B13" ref-type="bibr">Ratajska <italic toggle="yes">et al.</italic> 2023</xref>). The app features tips and notifications to ensure a smooth workflow, and all analyses may be stored, shared and retrieved by means of a tailor-made HTML report format.</p>
    <sec>
      <title>2.1 Data input</title>
      <p>Families can be added by uploading files in standard ped format, e.g. created with QuickPed (<xref rid="btae201-B19" ref-type="bibr">Vigeland 2022</xref>), or chosen from a dropdown list of basic cases. Additional information is entered in a table, including each member's phenotype, genotype, proband status, and age (of disease onset or censoring), all visualized in real-time on the pedigree plot.</p>
    </sec>
    <sec>
      <title>2.2 Model parameters</title>
      <p>The default variant frequency is 0.001, but it can be adjusted as needed. The inheritance pattern is made of two choices regarding chromosome (autosomal, X-linked) and dominance (dominant, recessive, incomplete). Penetrance specification may be done in two ways.</p>
      <list list-type="bullet">
        <list-item>
          <p><italic toggle="yes">Relative risk.</italic> We introduce a parametric version of COOL's (<xref rid="btae201-B1" ref-type="bibr">Belman <italic toggle="yes">et al.</italic> 2020</xref>) approach based on: (i) the baseline (phenocopy) lifetime risk and age of onset, and (ii) the hazard ratios over age. The user may enter these parameters directly, or provide incidence data from which optimal parameters are inferred by the program. Variant penetrances are automatically computed following a survival model (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S2</xref> for details).</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Liability classes.</italic> Penetrance values for each class may be written interactively or uploaded from a suitable file.</p>
        </list-item>
      </list>
    </sec>
    <sec>
      <title>2.3 Cosegregation evidence</title>
      <p>With all necessary information in place, shinyseg computes the full-likelihood Bayes factor (FLB) for the variant's pathogenicity (<xref rid="btae201-B17" ref-type="bibr">Thompson <italic toggle="yes">et al.</italic> 2003</xref>). We chose this metric over the cosegregation likelihood ratio (<xref rid="btae201-B8" ref-type="bibr">Mohammadi <italic toggle="yes">et al.</italic> 2009</xref>) because of its greater flexibility, not being limited to a single introduction of the variant. A key for translating the cosegregation evidence into the ACMG-AMP framework is provided, using <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning's (2016)</xref> thresholds. Furthermore, robustness of the results can be assessed with contour plots of the FLB when varying the analysis parameters.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>We showcase shinyseg by analyzing the pedigree in <xref rid="btae201-F1" ref-type="fig">Fig. 1A</xref>. This family is based on a real case where four members affected by a rare connective tissue disorder (onset: 30–60 years) were found to share a rare autosomal variant. Among the five unaffected individuals tested, two from the youngest generation were also carriers. Moreover, the proband's grandfather is likely an obligate carrier, but he remained asymptomatic until his death in his 40s. Penetrance estimates are not available. Henceforth, we will assume complete dominance and a population variant frequency of 0.001.</p>
    <fig position="float" id="btae201-F1">
      <label>Figure 1.</label>
      <caption>
        <p>(A) Medical pedigree showing phenotype (empty: unaffected; filled: affected; question mark: unknown), age (onset or censoring) and carriership status (+: carrier; –: non-carrier). Crossed individuals are deceased; the arrow indicates the proband. (B) Sensitivity analysis displaying contours of the FLB as a function of the risk in carriers and non-carriers under two penetrance models. The crosses indicate the main results, while the dotted lines enclose a region of reasonable parameter values.</p>
      </caption>
      <graphic xlink:href="btae201f1" position="float"/>
    </fig>
    <p>A naïve segregation analysis in this family could entail setting a single risk parameter for non-carriers (phenocopy rate) and another for carriers (penetrance). Conservative values of 0.001 and 0.90, respectively, yield an FLB of 3.2, which is inconclusive evidence for the variant's pathogenicity (FLB &lt; 8, <xref rid="btae201-B6" ref-type="bibr">Jarvik and Browning 2016</xref>). However, this conclusion is highly sensitive to the parameter values (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, left). In particular, reducing the carriers' risk amplifies the evidence, a consequence of the unaffected carriers.</p>
    <p>In order to better capture the apparent late-onset nature of the disease in this family, a possible approach is to introduce age-specific liability classes. Yet, with limited disease knowledge, this would require speculative estimates of the penetrance values. Furthermore, as each liability class adds multiple new parameters, sensitivity analyses become increasingly unwieldy.</p>
    <p>Instead, we use the <italic toggle="yes">relative risk</italic> mode of shinyseg, as it streamlines this process while ensuring transparent assumptions. For instance, using the same risk values as before and an age of onset for phenocopies of 60 ± 15 years, we obtain an FLB score of 30.3 under a proportional hazards model, i.e. constant relative risk. This indicates that our data actually provides moderate evidence for pathogenicity (FLB &gt; 16), a conclusion which is highly robust to the lifetime risk parameters (<xref rid="btae201-F1" ref-type="fig">Fig. 1B</xref>, right).</p>
  </sec>
  <sec>
    <title>4 Conclusion</title>
    <p>We present shinyseg, an app for clinical cosegregation analysis that emphasizes flexible penetrance specification and sensitivity analysis. Suited to varying levels of expertise, our app encourages transparent modelling assumptions and guides the user toward well-informed decisions.</p>
    <p>shinyseg is freely available at <ext-link xlink:href="https://chrcarrizosa.shinyapps.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.shinyapps.io/shinyseg</ext-link>, and runs in all common browsers. Documentation and complete source code can be found on <ext-link xlink:href="https://chrcarrizosa.github.io/shinyseg" ext-link-type="uri">https://chrcarrizosa.github.io/shinyseg</ext-link> and <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btae201_Supplementary_Data</label>
      <media xlink:href="btae201_supplementary_data.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work has been supported by the Research Council of Norway [321043 to D.E.U.].</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>All code and data are accessible at <ext-link xlink:href="https://github.com/chrcarrizosa/shinyseg" ext-link-type="uri">https://github.com/chrcarrizosa/shinyseg</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btae201-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Belman</surname><given-names>S</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>MT</given-names></string-name>, <string-name><surname>Spurdle</surname><given-names>AB</given-names></string-name></person-group><etal>et al</etal><article-title>Considerations in assessing germline variant pathogenicity using cosegregation analysis</article-title>. <source>Genet Med</source><year>2020</year>;<volume>22</volume>:<fpage>2052</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32773770</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Booth</surname><given-names>KT</given-names></string-name>, <string-name><surname>Askew</surname><given-names>JW</given-names></string-name>, <string-name><surname>Talebizadeh</surname><given-names>Z</given-names></string-name></person-group><etal>et al</etal><article-title>Splice-altering variant in COL11A1 as a cause of nonsyndromic hearing loss DFNA37</article-title>. <source>Genet Med</source><year>2019</year>;<volume>21</volume>:<fpage>948</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">30245514</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caputo</surname><given-names>SM</given-names></string-name>, <string-name><surname>Golmard</surname><given-names>L</given-names></string-name>, <string-name><surname>Leone</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach</article-title>. <source>Am J Hum Genet</source><year>2021</year>;<volume>108</volume>:<fpage>1907</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">34597585</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B4">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name><surname>Allaire</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal> shiny: web application framework for R. <year>2024</year>. R package version 1.8.1.1, <ext-link xlink:href="https://cran.r-project.org/package=shiny" ext-link-type="uri">https://cran.r-project.org/package=shiny</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cini</surname><given-names>G</given-names></string-name>, <string-name><surname>Carnevali</surname><given-names>I</given-names></string-name>, <string-name><surname>Sahnane</surname><given-names>N</given-names></string-name></person-group><etal>et al</etal><article-title>Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene</article-title>. <source>Cancer Genet</source><year>2021</year>;<volume>254-255</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">33516942</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarvik</surname><given-names>GP</given-names></string-name>, <string-name><surname>Browning</surname><given-names>BL.</given-names></string-name></person-group><article-title>Consideration of cosegregation in the pathogenicity classification of genomic variants</article-title>. <source>Am J Hum Genet</source><year>2016</year>;<volume>98</volume>:<fpage>1077</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">27236918</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lathrop</surname><given-names>GM</given-names></string-name>, <string-name><surname>Lalouel</surname><given-names>JM.</given-names></string-name></person-group><article-title>Easy calculations of lod scores and genetic risks on small computers</article-title>. <source>Am J Hum Genet</source><year>1984</year>;<volume>36</volume>:<fpage>460</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">6585139</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohammadi</surname><given-names>L</given-names></string-name>, <string-name><surname>Vreeswijk</surname><given-names>MP</given-names></string-name>, <string-name><surname>Oldenburg</surname><given-names>R</given-names></string-name></person-group><etal>et al</etal><article-title>A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example</article-title>. <source>BMC Cancer</source><year>2009</year>;<volume>9</volume>:<fpage>211</fpage>.<pub-id pub-id-type="pmid">19563646</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B9">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Owen</surname><given-names>J.</given-names></string-name></person-group> rhandsontable: interface to the ‘Handsontable.js’ library. <year>2021</year>. R package version 0.3.8, <ext-link xlink:href="https://cran.r-project.org/package=rhandsontable" ext-link-type="uri">https://cran.r-project.org/package=rhandsontable</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perrino</surname><given-names>PA</given-names></string-name>, <string-name><surname>Talbot</surname><given-names>L</given-names></string-name>, <string-name><surname>Kirkland</surname><given-names>R</given-names></string-name></person-group>; <collab>WGS500 Consortium</collab><etal>et al</etal><article-title>Multi-level evidence of an allelic hierarchy of USH2A variants in hearing, auditory processing and speech/language outcomes</article-title>. <source>Commun Biol</source><year>2020</year>;<volume>3</volume>:<fpage>180</fpage>.<pub-id pub-id-type="pmid">32313182</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petersen</surname><given-names>GM</given-names></string-name>, <string-name><surname>Parmigiani</surname><given-names>G</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>D.</given-names></string-name></person-group><article-title>Missense mutations in disease genes: a bayesian approach to evaluate causality</article-title>. <source>Am J Hum Genet</source><year>1998</year>;<volume>62</volume>:<fpage>1516</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">9585599</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B12">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ranola</surname><given-names>J</given-names></string-name>, <string-name><surname>Shirts</surname><given-names>B.</given-names></string-name></person-group> CoSeg R Package. <year>2016</year>. R package version 0.55, <ext-link xlink:href="https://r-forge.r-project.org/projects/coseg/" ext-link-type="uri">https://r-forge.r-project.org/projects/coseg/</ext-link> (23 April 2024, date last accessed).</mixed-citation>
    </ref>
    <ref id="btae201-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ratajska</surname><given-names>A</given-names></string-name>, <string-name><surname>Vigeland</surname><given-names>MD</given-names></string-name>, <string-name><surname>Wirgenes</surname><given-names>KV</given-names></string-name></person-group><etal>et al</etal><article-title>The use of segregation analysis in interpretation of sequence variants in SMAD3: a case report</article-title>. <source>Mol Genet Genomic Med</source><year>2023</year>;<volume>11</volume>:<fpage>e2107</fpage>.<pub-id pub-id-type="pmid">36495030</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>S</given-names></string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name></person-group>; <collab>ACMG Laboratory Quality Assurance Committee</collab><etal>et al</etal><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schäffer</surname><given-names>AA</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>SK</given-names></string-name>, <string-name><surname>Shriram</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Avoiding recomputation in linkage analysis</article-title>. <source>Hum Hered</source><year>1994</year>;<volume>44</volume>:<fpage>225</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">8056435</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stankute</surname><given-names>I</given-names></string-name>, <string-name><surname>Kazlauskiene</surname><given-names>M</given-names></string-name>, <string-name><surname>Blouin</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Co-segregation analysis and functional trial in vivo of candidate genes for monogenic diabetes</article-title>. <source>BMJ Open Diabetes Res Care</source><year>2022</year>;<volume>10</volume>:<fpage>e003038</fpage>.</mixed-citation>
    </ref>
    <ref id="btae201-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname><given-names>D</given-names></string-name>, <string-name><surname>Easton</surname><given-names>DF</given-names></string-name>, <string-name><surname>Goldgar</surname><given-names>DE.</given-names></string-name></person-group><article-title>A full-likelihood method for the evaluation of causality of sequence variants from family data</article-title>. <source>Am J Hum Genet</source><year>2003</year>;<volume>73</volume>:<fpage>652</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">12900794</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B18">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><source>Pedigree Analysis in R</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>2021</year>.</mixed-citation>
    </ref>
    <ref id="btae201-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vigeland</surname><given-names>MD.</given-names></string-name></person-group><article-title>QuickPed: an online tool for drawing pedigrees and analysing relatedness</article-title>. <source>BMC Bioinformatics </source><year>2022</year>;<volume>23</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">35672681</pub-id></mixed-citation>
    </ref>
    <ref id="btae201-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodbury-Smith</surname><given-names>M</given-names></string-name>, <string-name><surname>Deneault</surname><given-names>E</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>RKC</given-names></string-name></person-group><etal>et al</etal><article-title>Mutations in RAB39B in individuals with intellectual disability, autism spectrum disorder, and macrocephaly</article-title>. <source>Mol Autism</source><year>2017</year>;<volume>8</volume>:<fpage>59</fpage>.<pub-id pub-id-type="pmid">29152164</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
